Ultram

Pain Management

Ultram is primarily used to treat pain that is moderate to moderately severe. It belongs to a class of medications known as opioid analgesics, which work in the central nervous system to change how the body feels and responds to pain.

Healthcare providers may prescribe this medication for:

• Short-term relief of acute pain.
• Pain management when non-opioid treatments, such as over-the-counter pain relievers, do not provide sufficient relief.
• Situations where alternative treatments are inadequate or cannot be used due to side effects or medical history.

Because Ultram is an opioid, it is generally reserved for pain that is severe enough to require this level of treatment. It is intended for use in adults and is not recommended for use in children.

Mechanism of Action

Ultram belongs to a class of drugs known as opioid analgesics. It works primarily in the brain and spinal cord to provide relief from moderate to moderately severe pain.

The medication works through two main pathways:

• Opioid Receptor Binding: It binds to specific receptors in the brain called mu-opioid receptors. These receptors are part of the body's natural system for managing pain signals.
• Neurotransmitter Regulation: It affects the levels of certain chemical messengers in the nervous system, specifically norepinephrine and serotonin. By inhibiting the reuptake of these chemicals, the drug helps interfere with the transmission of pain signals between nerves.

While the exact way Ultram works is not completely understood, these combined actions help decrease the sensation of pain and the body's emotional response to it.

Common Side Effects

The most frequently reported side effects of Ultram include:

• Dizziness or lightheadedness
• Drowsiness
• Headache
• Nausea and vomiting
• Constipation
• Dry mouth
• Sweating
• Itching

Serious Side Effects

Seek immediate medical attention if you experience any of the following serious side effects:

• Slowed or shallow breathing
• Seizures
• Serotonin syndrome, which may involve agitation, hallucinations, fever, fast heart rate, muscle stiffness, or loss of coordination
• Signs of an allergic reaction, such as hives, skin rash, or swelling of the face, lips, or throat
• Fainting or extreme dizziness
• Confusion or extreme tiredness

Boxed Warnings

Ultram has several boxed warnings, which are the most serious warnings from the FDA:

• Addiction, Abuse, and Misuse: Use of this medication can lead to opioid use disorder, which can result in overdose and death.
• Respiratory Depression: Serious, life-threatening, or fatal breathing problems can occur, especially when starting the medication or after a dose increase.
• Accidental Ingestion: Even one dose taken accidentally, especially by a child, can be fatal.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can cause life-threatening withdrawal symptoms in the newborn.
• Interactions with Other Drugs: Using Ultram with benzodiazepines or other central nervous system depressants, including alcohol, can cause severe sedation, respiratory depression, coma, and death.

Other Serious Warnings

• Seizure Risk: Seizures have been reported in patients receiving Ultram within the recommended dosage range. The risk increases with higher doses or when taken with certain other medications, such as antidepressants or other opioids.
• Serotonin Syndrome: A potentially life-threatening condition called serotonin syndrome may occur, particularly when Ultram is used with other drugs that affect serotonin levels.
• Suicide Risk: Ultram should not be prescribed for patients who are suicidal or prone to addiction.
• Adrenal Insufficiency: Long-term opioid use may lead to a condition where the adrenal glands do not produce enough cortisol.
• Hypoglycemia: Serious cases of low blood sugar have been reported, sometimes requiring hospitalization.

Contraindications

Ultram is not for use in certain individuals, including:

• Children younger than 12 years of age.
• Children younger than 18 years of age following surgery to remove tonsils or adenoids.
• People with significant breathing problems, such as severe asthma or high carbon dioxide levels in the blood.
• People with a known or suspected blockage in the stomach or intestines, such as paralytic ileus.

Pregnancy

Using Ultram during pregnancy may lead to neonatal opioid withdrawal syndrome. This condition occurs when a newborn experiences withdrawal from the medication after being exposed to it in the womb. Symptoms can include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremors, vomiting, diarrhea, and failure to gain weight. If not recognized and treated, this condition can be life-threatening.

Ultram is not recommended for use during or immediately before labor and delivery. It can cause respiratory depression (slowed breathing) in the newborn.

Breastfeeding

Ultram is not recommended for use while breastfeeding. The medication and its active components pass into breast milk and can cause serious side effects in a nursing infant. These risks include:

• Extreme sleepiness or difficulty waking up
• Difficulty breastfeeding
• Limpness
• Serious breathing problems that may lead to death

If you are breastfeeding and taking this medication, seek emergency medical care immediately if your baby shows signs of increased sleepiness, limpness, or breathing difficulties.

It is important to discuss the risks and benefits of using Ultram with a healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

Available Forms

Ultram is supplied as an immediate-release tablet for oral use. This formulation is designed to release the medication into the system shortly after it is swallowed.

The active ingredient in Ultram, tramadol, is also available in several other oral formats, including:

• Immediate-release tablets
• Extended-release tablets
• Extended-release capsules

FDA Approval and Indications

Ultram (tramadol hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the management of pain severe enough to require an opioid analgesic and for which alternative treatments, such as non-opioid analgesics, are inadequate or not tolerated.

Boxed Warning

The FDA requires a Boxed Warning for Ultram due to several serious risks associated with opioid therapy:

• Addiction, Abuse, and Misuse: Use of Ultram exposes patients to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.
• Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, particularly during treatment initiation or following a dose increase.
• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in a fatal overdose.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.
• Interactions with CNS Depressants: Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants may result in profound sedation, respiratory depression, coma, or death.

Pediatric Restrictions

The FDA has issued safety communications restricting the use of tramadol in children. It is contraindicated in all children younger than 12 years of age. Additionally, it is contraindicated for post-operative pain management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. The FDA also recommends against use in adolescents between 12 and 18 years of age who have risk factors such as obstructive sleep apnea, obesity, or severe lung disease.

REMS and Scheduling

To ensure the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for these products. Ultram is also classified as a Schedule IV controlled substance under the Controlled Substances Act, indicating a potential for abuse and dependence.

Withdrawal Symptoms

If you have been taking Ultram regularly and stop using it abruptly, you may experience withdrawal symptoms. These symptoms can range from mild to severe and typically begin within a few hours to days after the last dose. Common signs of withdrawal include:

• Anxiety, nervousness, or panic attacks
• Difficulty falling or staying asleep
• Sweating and shivering
• Nausea, diarrhea, or stomach cramps
• Muscle aches and tremors
• Runny nose, sneezing, or coughing
• Goosebumps

In some cases, people may experience more serious symptoms such as hallucinations, unusual numbness or tingling sensations, or high blood pressure. Because of these risks, you should not stop taking this medication without talking to your doctor first.

Safe Discontinuation

To prevent or minimize withdrawal symptoms, healthcare providers usually recommend a tapering schedule. This involves slowly decreasing the amount of medication you take over a period of time. Following a professional tapering plan helps the body adjust safely to the absence of the drug.